TY - JOUR
T1 - Long-term immunosuppression management opportunities and uncertainties
AU - Wojciechowski, David
AU - Wiseman, Alexander
N1 - Funding Information:
A. Wiseman reports employment with Centura Transplant; consultancy agreements with CareDx, Hansa, Mallinkrodt, Natera, Novartis, and Veloxis; receiving research funding from Astellas, Bristol Meyer Squibb, Hookipa, Medeor, and Novartis; and serving as a scientific advisor or member of American Journal of Transplantation, the American Society of Nephrology NephSAP, and the American Society of Transplantation. D. Wojciechowski reports employment with University of Texas Southwestern Medical Center; consultancy agreements with eGenesis; receiving research funding from Astellas, BMS, CSL, Databean, Hookipa, Natera, Novartis, Oxford Immunotec, Qiagen, and Shire; and receiving honoraria from CareDx and Natera.
Publisher Copyright:
© 2021 by the American Society of Nephrology.
PY - 2021/8
Y1 - 2021/8
N2 - The long-term management of maintenance immunosuppression in kidney transplant recipients remains complex. The vastmajority of patients are treatedwith the calcineurin inhibitor tacrolimus as the primary agent in combinationwithmycophenolate, with orwithout corticosteroids.Atacrolimus troughtarget 5–8 ng/ml seems to be optimal for rejection prophylaxis, but long-term tacrolimus-related side effects and nephrotoxicity support the ongoing evaluation of noncalcineurin inhibitor–based regimens. Current alternatives include belatacept or mammalian target of rapamycin inhibitors. For the former, superior kidney function at 7 years post-transplant compared with cyclosporin generated initial enthusiasm, but utilization has been hampered by high initial rejection rates.Mammalian target of rapamycin inhibitors have yielded mixed results as well, with improved kidney function tempered by higher risk of rejection, proteinuria, and adverse effects leading to higher discontinuation rates.Mammalian target of rapamycin inhibitorsmay play a role in the secondary prevention of squamous cell skin cancer as conversion from a calcineurin inhibitor to an mammalian target of rapamycin inhibitor resulted in a reduction of new lesion development. Early withdrawal of corticosteroids remains an attractive strategy but also is associated with a higher risk of rejection despite no difference in 5-year patient or graft survival. Amajor barrier to long-termgraft survival is chronic alloimmunity, and regardless of agent used, managing the toxicities ofimmunosuppressionagainst the risk of chronic antibody-mediated rejectionremains a fragile balance.
AB - The long-term management of maintenance immunosuppression in kidney transplant recipients remains complex. The vastmajority of patients are treatedwith the calcineurin inhibitor tacrolimus as the primary agent in combinationwithmycophenolate, with orwithout corticosteroids.Atacrolimus troughtarget 5–8 ng/ml seems to be optimal for rejection prophylaxis, but long-term tacrolimus-related side effects and nephrotoxicity support the ongoing evaluation of noncalcineurin inhibitor–based regimens. Current alternatives include belatacept or mammalian target of rapamycin inhibitors. For the former, superior kidney function at 7 years post-transplant compared with cyclosporin generated initial enthusiasm, but utilization has been hampered by high initial rejection rates.Mammalian target of rapamycin inhibitors have yielded mixed results as well, with improved kidney function tempered by higher risk of rejection, proteinuria, and adverse effects leading to higher discontinuation rates.Mammalian target of rapamycin inhibitorsmay play a role in the secondary prevention of squamous cell skin cancer as conversion from a calcineurin inhibitor to an mammalian target of rapamycin inhibitor resulted in a reduction of new lesion development. Early withdrawal of corticosteroids remains an attractive strategy but also is associated with a higher risk of rejection despite no difference in 5-year patient or graft survival. Amajor barrier to long-termgraft survival is chronic alloimmunity, and regardless of agent used, managing the toxicities ofimmunosuppressionagainst the risk of chronic antibody-mediated rejectionremains a fragile balance.
UR - http://www.scopus.com/inward/record.url?scp=85113863789&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85113863789&partnerID=8YFLogxK
U2 - 10.2215/CJN.15040920
DO - 10.2215/CJN.15040920
M3 - Article
C2 - 33853841
AN - SCOPUS:85113863789
SN - 1555-9041
VL - 16
SP - 1264
EP - 1271
JO - Clinical Journal of the American Society of Nephrology
JF - Clinical Journal of the American Society of Nephrology
IS - 8
ER -